Bot Chart, page-9751

BOT will be 24c and then some in 2024. It got to 21c prior to anticipated approval in September, so you will see a repeat of that as we get closer to the new approval date. Most likely even higher because we now KNOW that the FDA is happy with the science and just need some administrative fixes tidied up. BOT is in the doldrums presently because until approval (which could be as much as 8-9 months away), they simply can't do anything. They are subject to the day-to-day market fluctuations with all the issues going on in the world, and not being ale to do anything about it UNTIL the FDA approve SOFDRA. The only risk of not holding in the meantime is you could miss out on some announcement about a merger or buyout come along. Probably not likely, but potential is there. Of course if you hold, the price could go lower in the interim before going higher once more. But as they say, you only make a loss if you sell!

Once BOT starts selling SOFRDA it'll approach a much larger MC. If they only sell the same amount that Kaken are already selling in Japan (a place a third of the size of the US) then you can expect revenue in excess of $100m/pa. Even with a modest 10xPE, BOT will be a $B MC, let alone if it has a PE of 20-30x as I see others have mentioned here before as typical for a bio PE.